Loading
Total declarations
Companies
▲ Purchases (3 ops.)
▼ Sales (3 ops.)
Latest filing published 04 Mar 2022 for Humanigen, INC, €84k.
Filing timeline
BuySaleCameron Durrant
Insider track record
Disclosed buys
3
Disclosed sells
3
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
No signal scores available.
Cameron Durrant: trading record in brief
This profile gathers the share dealings of Cameron Durrant across 4 companies, led by Humanigen, Inc, Anavex Life Sciences Corp. and Immune Pharmaceuticals Inc. Over a trading history stretching from 18 June 2009 to 2 March 2022, the count stands at 20 filings.
Market trades split into 3 purchases (€132k) and 3 sales (€1.4M). Netting one side against the other leaves €1.3M of net selling. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 10 share grants. So far in 2022, the count stands at 1 purchase and no sales.
The median purchase comes to €39k.
On 4 March 2022 came the latest disclosure, an open-market purchase for €84k in Humanigen, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Cameron Durrant
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations2 total
40,000 shares@ US$2.34100.0% of flowCommon StockSEC:0001214659-22-003623:0
Canonical exit: 31 May 2022 (T+90)
111,441 shares0Common StockSEC:0001214659-21-006640:0
2 of 2 declarations
